Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemolink in Primary CABG Surgery
NCT00038454Phase 3Suspended
- Sponsor
- Hemosol Inc.
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of Hemoglobin raffimer in anemia (2 arms), sponsored by Hemosol Inc. Primary endpoint: Avoidance of allogeneic RBC transfusion during and following primary CABG surgery. Status: suspended.
02
Drugs
Hemoglobin raffimer
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00038454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038454.